Analyst Price Targets — FULC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 6:38 pm | Gregory Renza | Truist Financial | $17.00 | $8.96 | TheFly | Fulcrum Therapeutics price target lowered to $17 from $18 at Truist |
| December 11, 2025 2:04 pm | — | Truist Financial | $18.00 | $12.65 | TheFly | Fulcrum Therapeutics price target raised to $18 from $14 at Truist |
| December 8, 2025 2:04 pm | — | Stifel Nicolaus | $25.00 | $14.07 | TheFly | Fulcrum Therapeutics price target raised to $25 from $20 at Stifel |
| December 8, 2025 1:42 pm | Kristen Kluska | Cantor Fitzgerald | $24.00 | $13.74 | TheFly | Fulcrum Therapeutics price target raised to $24 from $15 at Cantor Fitzgerald |
| December 8, 2025 1:18 pm | — | RBC Capital | $10.00 | $14.06 | TheFly | Fulcrum Therapeutics price target raised to $10 from $7 at RBC Capital |
| December 8, 2025 11:41 am | — | Piper Sandler | $23.00 | $8.90 | TheFly | Fulcrum Therapeutics price target raised to $23 from $16 at Piper Sandler |
| December 8, 2025 11:15 am | — | H.C. Wainwright | $25.00 | $8.90 | TheFly | Fulcrum Therapeutics price target raised to $25 from $18 at H.C. Wainwright |
| November 24, 2025 12:21 pm | — | Truist Financial | $14.00 | $11.29 | TheFly | Fulcrum Therapeutics initiated with a Buy at Truist |
| November 24, 2025 11:37 am | Andrew Fein | H.C. Wainwright | $18.00 | $11.29 | StreetInsider | Fulcrum Therapeutics (FULC) PT Raised to $18 at H.C. Wainwright |
| October 30, 2025 11:12 am | — | Piper Sandler | $16.00 | $9.36 | TheFly | Fulcrum Therapeutics price target raised to $16 from $12.50 at Piper Sandler |
Latest News for FULC
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the Leerink Partners Global Healthcare Conference in Miami, FL on Tuesday, March 10, 2025 at…
Fulcrum Therapeutics (FULC) pivots to pociredir for severe sickle cell disease after discontinuing losmapimod. Pociredir's Phase 1 PIONEER data shows 7/12 patients hitting the ≥20% HbF threshold, but mean HbF just misses the mark. FULC's valuation is tied almost entirely to pociredir, with a risk-adjusted NPV of $136 million and $352.3 million in cash.
Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript
Fulcrum's new sickle cell trial data show higher hemoglobin levels and no serious safety concerns in sickle cell disease patients.
― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FULC.
U.S. House Trading
No House trades found for FULC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.